Mahta Barekatain,Linda C. Johansson,Jordy Homing Lam,Hao Chang,Anastasiia Sadybekov,Gye Won Han,Joseph Russo,Joshua Bliesath,Nicola L. Brice,Mark Carlton,Kumar Singh Saikatendu,Hongyang Sun,Sean T. Murphy,Holger Monenschein,Hans H. Schiffer,Petr Popov,Corinne A. Lutomski,Carol V. Robinson,Zhi‐Jie Liu,Tian Hua,Vsevolod Katritch,Vadim Cherezov
出处
期刊:Science Signaling [American Association for the Advancement of Science (AAAS)] 日期:2024-12-03卷期号:17 (865)
GPR6 is an orphan G protein–coupled receptor with high constitutive activity found in D2-type dopamine receptor–expressing medium spiny neurons of the striatopallidal pathway, which is aberrantly hyperactivated in Parkinson’s disease. Here, we solved crystal structures of GPR6 without the addition of a ligand (a pseudo-apo state) and in complex with two inverse agonists, including CVN424, which improved motor symptoms in patients with Parkinson’s disease in clinical trials. In addition, we obtained a cryo–electron microscopy structure of the signaling complex between GPR6 and its cognate G s heterotrimer. The pseudo-apo structure revealed a strong density in the orthosteric pocket of GPR6 corresponding to a lipid-like endogenous ligand. A combination of site-directed mutagenesis, native mass spectrometry, and computer modeling suggested potential mechanisms for high constitutive activity and inverse agonism in GPR6 and identified a series of lipids and ions bound to the receptor. The structures and results obtained in this study could guide the rational design of drugs that modulate GPR6 signaling.